Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells

Bioconjugate Chemistry
E B SweeneyJ C vanderSpek

Abstract

Interleukin 7 (IL-7) induces the proliferation of B cell progenitors in long-term bone marrow cultures, promotes the growth of resting fetal and adult thymocytes, and costimulates mature human T cell proliferation. IL-7 also induces cell growth in hematologic malignancies such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, and Sezary syndrome. We have constructed a recombinant fusion protein, DAB389 IL-7, composed of the catalytic and transmembrane domains of diphtheria toxin (DT), fused to IL-7. We demonstrate that DAB389 IL-7 is selectively cytotoxic for only those cells bearing the IL-7 receptor and that entry into target cells is mediated through the receptor. The nontoxic mutant, DA(E149S)B389 IL-7, was constructed and used to demonstrate that the catalytic domain of DT is responsible for the ADP ribosylation of elongation factor 2 that results in cytotoxicity. Finally, we demonstrate that DA(E149S)B389 IL-7 induces the growth of IL-7-dependent cells, verifying the bioactivity of the IL-7 binding domain of DAB389 IL-7. We propose that DAB389 IL-7 may be an important reagent in studying the IL-7--IL-7 receptor complex and may possess potential as a therapeutic agent against IL-7 r...Continue Reading

References

Jan 1, 1977·Annual Review of Biochemistry·A M Pappenheimer
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P HeskethT Woodworth

❮ Previous
Next ❯

Citations

Feb 23, 2002·Cellular Signalling·Larry CosenzaFrancine Foss
Jul 16, 2005·Leukemia & Lymphoma·Joao T BarataVassiliki A Boussiotis
Jul 5, 2005·Expert Opinion on Investigational Drugs·R J Kreitman
May 19, 2009·Journal of Immigrant and Minority Health·Jill S LittCarolyn DiGuiseppi
Aug 19, 2008·Journal of Immigrant and Minority Health·Katherine StandishSandro Galea
May 2, 2006·Journal of Immigrant and Minority Health·Julie EarlyThomas A Arcury
Apr 4, 2013·Bioorganicheskaia khimiia·S I RomaniukS V Komisarenko
Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Motomi YamazakiMamoru Watanabe
Nov 5, 2019·Frontiers in Microbiology·Fatemeh ShafieeAli Jahanian-Najafabadi
Aug 27, 2003·Seminars in Oncology·Arthur E FrankelStephen H Leppla
Nov 26, 2009·Journal of Immunological Methods·Tatiana MareevaYuri Sykulev

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.